Inhibitors of NADH–ubiquinone reductase: an overview  by Degli Esposti, Mauro
 .Biochimica et Biophysica Acta 1364 1998 222–235
Inhibitors of NADH–ubiquinone reductase: an overview
Mauro Degli Esposti )
Department of Biochemistry and Molecular Biology, Monash Uni˝ersity, 3168 Clayton, Victoria, Australia
Received 10 October 1997; revised 5 December 1997; accepted 9 December 1997
Abstract
This article provides an updated overview of the plethora of complex I inhibitors. The inhibitors are presented within the
broad categories of natural and commercial compounds and their potency is related to that of rotenone, the classical
inhibitor of complex I. Among commercial products, particular attention is dedicated to inhibitors of pharmacological or
toxicological relevance. The compounds that inhibit the NADH–ubiquinone reductase activity of complex I are classified
according to three fundamental types of action on the basis of available evidence and recent insights: type A are antagonists
of the ubiquinone substrate, type B displace the ubisemiquinone intermediate, and type C are antagonists of the ubiquinol
product. q 1998 Elsevier Science B.V.
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1. Introduction
 .NADH–ubiquinone reductase EC 1.5.6.3 is the
energy-conserving enzyme complex that is com-
w xmonly known as complex I 1–3 . Complex I embod-
ies the first phosphorylation site of mitochondria and
Abbreviations: CCCP, carbonyl cyanide-m-chlorophenylhy-
drazone; DB, decyl-Q analogue; DCCD, docyclohexylcarbodi-
imide; DCIP, dichlorophenolindophenol; DNP, 2,4-dinitrophenol;
DPI, diphenyleneiodonium; DQ, duroquinone; I , inhibitor con-50
q  .centration producing 50% inhibition; HPP , 4- 4-chlorophenyl -
 .1-4- 4-fluorophenyl -4-oxobutyl-pyridinium; MOA, methoxy-
acrylate; MPPq, 1-methyl-4-phenyl-pyridinium; MPTP, 1-
methyl-4-phenyl-1,2,3,4,-tetrahydropyridine; 2M-TIO, 2-methyl-
 . w x6- 2-thienyl imidazo 2,1-b thiazole; NP, 4-nonylphenol; Q,
ubiquinone; Q-1, Q-2, ubiquinone-1, -2; QH , ubiquinol; RET,2
reverse electron transfer to NADq; SAN, Sandoz quinazoline
compounds; SMP, submitochondrial particles; TDS, tridecyl stig-
matellin; TIQ, tetrahydroisoquinoline; UBQ, undecyl-Q analogue
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is first among the respiratory complexes also in the
number of inhibitors. Over sixty different families of
compounds are known to inhibit complex I, but
recent articles have considered only a fraction of
w xthese 4–8 , while the reviews on complex I in-
w xhibitors are becoming dated 9,10 . The purpose of
this article is to provide an overview of the plethora
of complex I inhibitors. To concisely present a large
body of information, I introduce first a broad distinc-
tion among compounds of natural and commercial
origin, and then propose a new functional classifica-
 .tion of complex I inhibitors based on ubiquinone Q
reaction sites.
2. The plethora of complex I inhibitors
The number of compounds that inhibit complex I
is ever increasing, and it is impossible to classify
them in chemical terms. Tables 1 and 2 report the
0005-2728r98r$19.00 q 1998 Elsevier Science B.V. All rights reserved.
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diverse inhibitors divided into natural and commer-
cial products with potency related to that of rotenone,
w xthe classical inhibitor of complex I 4,9,10 . The
relative potency of natural inhibitors is often ex-
pressed in terms of the ratio with the K of rotenoneI
 .Table 1 , that is 4 nM in our standard assay of
w x w xNADH–Q reductase 8 . See Refs. 4,56 for a review
on compounds that inhibit complex I among other
enzymes, e.g. sulphydryl reagents.
3. Characteristics of complex I inhibition
A few compounds inhibit NADH interaction, but
are not specific for complex I since they also affect
 w x.other dehydrogenases e.g. rhein 9,10,23 . There-
fore, the great majority of complex I inhibitors act on
the NADH–Q reductase activity, which is the limit-
w xing reaction in NADH oxidation 4,57,58 , without
inhibiting the NADH–ferricyanide reductase activity
w x4,9,59,13 . The inhibition of complex I can be mea-
sured in different ways. In coupled submitochondrial
particles it is possible to follow the energy-dependent
 . q w xreverse electron transfer RET to NAD 60,61 .
RET assays are delicate and have been employed in
w xtoxicological studies 62 . Dichlorophenolindophenol
 .DCIP and naphtoquinones such as menadione have
been used as artificial electron acceptors for complex
w xI activity 5,31,33,55,63,64 , but their physiological
w xsignificance is limited 4,56 . NADH oxidase or
NADH–Q reductase are the recommended assays for
a proper evaluation of complex I inhibitors. The
NADH–Q reductase activity is best assayed with
 .  .decyl-Q DB or undecyl-Q UBQ as electron accep-
w xtor substrates 25 . The I values of inhibitors ob-50
served with these Q analogues are generally larger
w xthan those obtained in the NADH oxidase assay 31
or with the hydrophilic Q-1. This latter Q analogue
w xproduces fast rates 25,48,63,65,66 but reacts incom-
w xpletely with complex I 25,67 .
 .Submitochondrial particles SMP are the system
w xof choice in the study of complex I inhibition 4,8,56 .
In fact, isolated complex I is largely inactivated by
detergent extraction and its reactivity with quinones
w xand inhibitors is substantially altered 4,56 . Beef
heart SMP usually have 0.03–0.04 nmol per mg of
w x protein of active complex I 4,8,13,59 see, however,
w x.Ref. 68 . This implies that the minimal I for a50
potent inhibitor is around 0.02 nmolrmg and the
observed I values approach the true K at particle50 I
w xconcentrations below 0.02 mgrml 8,68 . Because
the minimal concentration of complex I that allows
reliable measurements is 0.1 nM, the sub-nanomolar
w xI values reported in 6,15 may reflect stoichiomet-50
ric inhibition.
With regard to species-specificity, insect and fish
mitochondria are particularly sensitive to complex I
w xinhibition 6,33,69 , which rationalizes the traditional
w xuse of rotenoids as fish and insect poisons 10,69 . By
contrast, mitochondria of fungi and plants are natu-
w xrally resistant to complex I inhibitors 7,22,70 .
Among bacteria, R. capsulatus and P. denitrificans
display inhibitory sensitivities that are close to those
w xof mammalian mitochondria 7,54,71,72 , but E.coli
is extremely insensitive to rotenone and other in-
w xhibitors 7,73 . At the cellular level, complex I func-
tion is particularly crucial in tissues such as neurons
and pancreatic islet beta cells that heavily rely upon
wmitochondrial ATP and NAD-linked pathways 74–
x76 . The potent cytotoxic effect of inhibitors in can-
w xcer cell cultures 77–79 suggests that complex I
activity is delicate also in transformed cells, probably
because they usually have a smaller number of mito-
chondria than their parent normal cells.
4. Complex I inhibitors of natural origin
In essence, the structure of potent natural in-
hibitors of complex I has a modular similarity with
ubiquinone, with a cyclic ‘head’ corresponding to the
ubiquinone ring and a hydrophobic ‘tail’. Natural
variations within each family of inhibitors is nor-
mally restricted to substitutions and degrees of oxy-
genation of the tail see also the contribution of
w x.Miyoshi 80 .
4.1. Rotenoids
Rotenone is the most potent member of the
rotenoids, a family of isoflavonoids extracted from
w xLeguminosae plants 12,70,81 , and since the early
w xreports 69,81 has become the classical inhibitor of
w xcomplex I 1,4,10,56,68 . Rotenone inhibition is
w xmarkedly time-dependent 4,9,12 , which easily leads
to under-estimations of its potency—a K as low asI
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Table 1
Complex I inhibitors of natural origin and their analogues
 .Family of Source Potent I values in beef K M Assay Relative Notes and Refs.50 I
acompounds representative mitochondria system potency
 . w xRotenoids plants e.g. Derris Rotenone 0.07 nmolrmg 4 nM NADH–Q 1 insecticide and pesticide 7,8,11
0.04 nmolrmg NADH–O2
w xDeguelin 4.2 nmolrmg NADH–Q 0.02 insecticide 12
synthetic Analogue 13 0.35 nmolrmg NADH–Q 1
b w xPiericidins Streptomyces Piericidin A 0.06 nmolrmg 1.0 nM NADH–Q )4 two sites, Q antagonist 7,8,13
0.03 nmolrmg 0.6 nM NADH:O2
w xsynthetic Ubicidin-3 0.17 nmolrmg 1.5 nM NADH:O 2 142
w xsynthetic hydroxypyridine 0.23 nmolrmg NADH:O 1 152
analogue 21
w xAnnonaceous plants Rolliniastatin-1 0.03 nmolrmg 0.3 nM NADH–Q 13 most potent and specific 8
 .acetogenins e.g. Annona
w xRolliniastatin-2 0.06 nmolrmg 0.6 nM NADH–Q-1 6.7 action different from rotenone 8
or Bullatacin
w xOtivarin 0.2 nmolrmg 0.9 nM NADH–Q )1 action similar to rotenone 8
w xMyxobacterial Polyangium Phenoxan 0.04 nmolrmg NADH–Q 2 7
antibiotics
w xPolyangium Thiangazole 0.04 nmolrmg NADH–Q 2 7
w xCystobacter Myxalamid PI 15 nmolrmg NADH–Q 0.006 7
w xMyxococcus Phenalamid A 0.6 nmolrmg NADH–Q 0.12 72
b w xStigmatella Aurachin A 8.0 nmolrmg NADH–Q 0.01 Q antagonist 7
b w xMyxococcus Myxothiazol 20 nmolrmg 0.1 mM NADH–Q 0.04 Q antagonist 16,17
b w xStigmatella Stigmatellin 100 nmolrmg NADH–Q 0.004 Q antagonist 16
b w xsynthetic TDS 40 nmolrmg 0.2 mM NADH–Q 0.02 Q antagonist 16,17
w xOther Streptomyces Aureothin 0.3 nmolrmg NADH–Q 0.23 7
antibiotics
b w xBipolaris Cochlioquinone B 83 nmolrmg NADH:O 0.002 Q antagonist 182
b w xStrobilurus Mucidin )100 nmolrmg NADH–Q 0.001 Q antagonist 16
w xPterula Pterulone 36 mM NADH:O -0.002 antifungal 192
 . w xVanilloids plants e.g. Capsicum Capsaicin 20–30 mM NADH–Q -0.001 irritant, analgesic 20,21
NADH:O2
w xsynthetic analogue 37 6.2 nmolrmg NADH–Q 0.27 22
c w xPlant products rhubarb Rhein 30 mM 2 mM NADH:O -0.002 NADH antagonist 232
w xopium Papaverine 5 mM NADH–Q-1 0.006 vasodilator 24
w x w xUbiquinones synthetic Ubiquinone-2 2 mM NADH–Q-1 0.003 25,26 27,28
w xsynthetic Ubiquinone-3 40 mM NADH–Q -0.001 26,27
w xsynthetic Idebenone 0.4 mM NADH–Q 0.01 nootropic drug 28
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w x1 nM has been reported 68 . Detailed measurements
w14 xwith C rotenone have indicated a specific binding
titre of 0.06–0.07 nmolrmg protein in beef heart
w xSMP 82 and I values approach this titre when the50
particle concentration is above 0.1 mgrml in the
assay. Binding studies by Singer and coworkers have
indicated that amytal, piericidin A and 1-methyl-4-
 q.phenyl-pyridinium MPP displace rotenone from
w xits specific site in complex I 4,9,56,82 . Results with
w x w xphotoaffinity labelling 83 , fluorescent dyes 84 and
w3 x w xH dihydrorotenone 6,85 have later clarified that
rotenone does not compete with Q analogues. Pho-
toaffinity labelling data have suggested that the ND1
subunit could be directly involved in forming the
w xrotenone binding site 86,87 . Investigations on hu-
man disease mutations partly sustain this possibility
and indicate that also the ND4 subunit could be
w xinvolved in rotenone binding 88,89 .
4.2. Piericidins
Piericidins are 2,3-dimethoxy-4-hydroxy-5-methy-
6-polyprenyl-pyridine antibiotics produced by some
w xStreptomyces strains 90 that have contributed exten-
sively to the definition of the enzyme properties of
w xcomplex I 4,9–11,13,14,56,91–94 . The methylation
of the hydroxyl group at position 10 of the tail in
natural piericidin B and D seems to reduce potency
w x11,93 , consistent with the diminished potency of the
6-isoprenyl derivatives of piericidins, usually called
w xubicidins 14,92 . The close similarity with
ubiquinone renders piericidin A an effective inhibitor
 w xof several Q-reacting enzymes see Ref. 16 and
.reference therein . Complex I, however, remains the
most specific site of piericidin inhibition, with a K I
w x w xranging between 0.6 14,91 and 1 nM 8 . Studies
w14 xwith C piericidin A have indicated that complex I
has two binding sites for the inhibitor in the native
w xmembrane 13,94 , one of which inhibits energy-de-
w xpendent RET more potently than NADH oxidase 94 .
The tight binding of piericidin A to complex I essen-
tially prevents its displacement by rotenone and amy-
w xtal 4,9,11 . However, a partial displacement of bound
piericidin A has been obtained with certain analogues
q w xof MPP 4,95 , whilst the acetogenin rolliniastatin-2
w xis mutually exclusive with piericidin A 8 . New
information on the molecular interaction of piericidin
will be hopefully obtained with the resistant mutants
w xrecently described in Rhodobacter 71 .
4.3. Annonaceous acetogenins
Natural products called annonaceous acetogenins
derive from Annonaceae plants such as custard apple
w x5,8,77,79,96,97 . They have been initially character-
w xized as antitumoral agents 77,79 , and subsequently
recognized as specific inhibitors of mammalian com-
w xplex I 5,8,97 . The family of annonaceous aceto-
genins now includes nearly 200 different compounds,
some of which are extremely potent inhibitors
w x5,8,77,96–98 . Their global structure consists of an
aliphatic backbone of 35–37 carbons terminating with
a substituted g-lactone and containing a central nu-
w xcleus of one or two tetrahydrofuran groups 79,96 .
Various hydroxyl groups are distributed along the
molecule and seem to be essential for inhibition
w x5,77,96 . However, little information is available on
the structure–activity of these inhibitors, in part due
to the limited natural variations that are confined to
the number of hydroxyl groups and the structure or
stereochemistry of the tetrahydrofuran nucleus
w x77,79,96 . This tetrahydrofuran nucleus is likely to
be fundamental for biological activity, since it could
 w x.mimic the quinoid head of ubiquinone cf. Ref. 5 .
The part of the molecule with the lactone could
correspond to the hydrophobic tail of other inhibitors
such as piericidins, whereas the aliphatic part could
essentially act as a lipophilic anchor.
Notes to Table 1:
aPotency relative to that of rotenone measured under the same conditions in beef mitochondria or submitochondrial particles. The relative
potency is measured using the ratio of the K values, when they are available. NADH–Q reductase is with hydrophobic Q analogues suchI
as DB, UBQ and Q-2.
bThese inhibitors are general Q antagonists since they inhibit also other Q-reacting enzymes, especially cytochrome bc complex and1
bacterial reaction centres.
cRhein specifically inhibits the rotenone-insensitive reduction of ferricyanide and acts as a NADH antagonist in soluble mitochondrial
w xNADH dehydrogenase, as well as in other dehydrogenases 9,23 .
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Table 2
Commercial and synthetic inhibitors of complex I
a bType of compounds and main use Representative inhibitor Minimal I Assay system Relative potency Refs.50
( )a Pesticides
Acaricides and insecticides Sandoz 547A 2 nM NADH–Q-1 )2 this work
Pyridaben 2.4 nM NADH–Q-1 2 this work
Fenpyroximate 4.6 nM NADH–Q-1 1.1 this work
w x18 nM NADH–Q 1.4 22
Tebufenpyrad 6 nM NADH–Q-1 ca. 1 this work
w xFenazaquin 20 nM NADH–Q-1 0.5 5
w xBenzimidazole 3 nM NADH–Q 1.4 7
y2 w xPyrethroid insecticides Cyhalothrin 0.6 mM NADH–DQ 4=10 29
y4 w xInsecticide synergists 6-chloro-benzothiadiazole 0.1 mM NADH:O 1=10 302
y3 . w xAntihelmintic mimics 2M-TIO compound 10 40 mM NADH–Q-1 6=10 31
( )b Drugs and toxins
y5 . w xSedative drugs Amytal barbiturate 0.2 mM NADH–Q-1 5=10 31,32
y4 .Analgesic drugs Meperidine Demerol 0.1 mM NADH–Q-1 1=10 this work
w xMeperidine analogue 49 0.8 mM NADH–Q 0.6 33
q y5 w xSynthetic neurotoxins MPP 0.3 mM NADH:O 3=10 342
y5 w x w x2–4 mM NADH–Q -10 35,36 37
q y2 w xdecyl-MPP 1.7 mM NADH:O 2=10 362
w xMQ18 0.2 mM NADH–Q-1 0.1 37
y5 w x2-methylharmine 0.18 mM NADH:O 6=10 382
y5 w xNatural neurotoxins TIQ 2 mM NADH:O -10 39,402
y5 w xAminoethyl cysteineketamine 1.3 mM NADH:O -10 392
y2 w xNeuroleptic drugs Haloperidol 3 mM NADH–Q-1 2=10 41,42
q y3 w xDrug metabolite HPP 15 mM NADH–Q-1 2=10 42
y3 w xMouth wash antiseptic Dequalinium chloride 11 mM NADH:O 3=10 432
y3 w xAntihistaminic drugs Cinnarizine 5–10 mM NADH–Q-1 1=10 44
y3 w xAntianginal drugs Ranolazine 23 mM NADH–Q-1 2=10 45
( )c Phenolic chemicals
y3 w xRodenticides Vacor 50 mM NADH–Q 5=10 46
y3Phenols: pollutant nonyl-phenol 20 mM NADH–Q 3=10 this work
y5pollutant catechol 0.4 mM NADH–Q 2=10 this work
y4 w xuncoupler dinitrophenol 0.15 mM NADH–Q-1 1=10 47
y4uncoupler CCCP 85 mM NADH–Q-1 2=10 this work
( )d Q antagonists
y2 w xAcridones 4-s-butyl analogue 1.4 mM NADH–Q-1 5=10 48
w x7-chloro-4-octyloxy analogue 0.2 mM NADH–Q-1 -0.1 48
w xQuinolones 2-undecyl-3-methyl analogue 20 nM NADH–Q-1 ca. 1 49
w xQuinolines 4-hydroxy analogue 37 10 nM NADH:O ca. 1 152
X y2 w xPhenylpyridines 4 -heptyl analogue 1.7 mM NADH:O 2=10 362
( )e Fluorescent dyes
X w xFluoresceins Erythrosin 5 -iodoacetamide 20 nM NADH–O 0.8 502
y3 w xAcridines Safranine 17 mM NADH–Q 2=10 51
y2 .  . w xCarbocyanines diOC 3 D-272 1.5 mM NADH–Q 5=10 515
 . w xdiOC 3 80 nM NADH–O 0.2 506 2
( )f Group reagents
c w xFlavin reagent DPI 0.23 mM NADH–Q-1 -0.1 52
y4 w xCarboxyl reagent DCCD 0.1 mM NADH–Q-1 1=10 53
y5 w xMetal chelator o-phenantroline 0.25 mM NADH–Q 4=10 54
( )M. Degli EspostirBiochimica et Biophysica Acta 1364 1998 222–235 227
Acetogenins with two adjacent tetrahydrofurans
such as rolliniastatin-1 and rollimembrin are the most
potent inhibitors of complex I, with K values aroundI
w x0.3 nM 8,98 . Next in potency is rolliniastatin-2 or
w xbullatacin 5,8,77,96 , which has a K similar to thatI
 .of piericidin A Table 1 and is consistently non-ex-
w xclusive with rotenone 8 . Indeed, the sensitivity to
rolliniastatin-2 is unaltered in Rhodobacter mutants
w x71 and human pathological conditions showing re-
w x w xsistance to rotenone 99 . Besides rolliniastatin-2 8 ,
a few acetogenins are likely to be non-exclusive with
 .rotenone E. Estornell, personal communication ,
while many others seem to act like rotenone, depend-
ing in particular on the presence of an hydroxy group
near the substituted lactone e.g. squamocin or oti-
w x.varin vs. rolliniastatin-2 8 .
4.4. Myxobacterial antibiotics
Myxobacteria are a precious source of potent mito-
w xchondrial inhibitors 100 . Myxothiazol and stig-
matellin are most specific for cytochrome bc com-1
w xplexes, but inhibit also complex I 16 . Myxothiazol
w xhas a K of 0.1 mM in beef SMP 16,17 and is moreI
 .potent than stigmatellin Table 1 . Both inhibitors
seem to compete for a common site in complex I
w xwhich overlaps that of rotenone only in part 6,17
and specifically interferes with the ubiquinol product
w x31,58 . Myxobacteria produce several other antibi-
w xotics that inhibit complex I: aurachins 100 , myx-
w x w x w xalamid 101 , phenalamid 102 , phenoxan 103 and
w xthiangazole 104 . The quinolone aurachins have been
found to be more specific for bacterial quinol oxi-
w xdases and cytochrome bc and bf complexes 105
 w x.than for complex I cf. Ref. 7 . Conversely, phe-
noxan and thiangazole seem to be most specific for
complex I, with a potency about two-fold stronger
w xthan that of rotenone in mammalian mitochondria 7
 .Table 1 .
4.5. Other antibiotics
Table 1 reports other antibiotic inhibitors such as
 . waureothin Z, E -2-methoxy-3,5-dimethyl-6- tetrahy-
w  . xdro-4- 2-methyl-3- 4-nitrophenyl -2-propenylidene -2-
x 4 w xfuranyl -4h-pyran-4-one 106 which seems to act
w xlike rotenone 7 . Among cochlioquinones, a family
of fungal toxins of polycyclic structure, cochlio-
quinone B seems to be specific for the NADH–Q
w xreductase activity 18 .
4.6. Vanilloids and other plant products
 . w .Capsaicin E -n- 4-hydroxy-3-methoxyphenyl -
x 4methyl -8-methyl-6-nonenamide is the most repre-
sentative member of the vanilloids, pungent sub-
w xstances extracted from hot peppers 107,108 . Vanil-
loids are widely used in neurobiology studies see
w x .Ref. 107 for a review , and have applications as
topical analgesics, food additives and even sprays for
personal defence. The mitochondrial toxicity of cap-
w xsaicin derives from its inhibition of complex I 20 .
Compared to other natural products, capsaicin is a
weak inhibitor I values around 30 mM in mam-50
w x.malian SMP 7,21,22,31 , but shows the rare prop-
erty of competitive inhibition vs. Q substrates in
w xisolated complex I 20 . In SMP, the kinetic be-
haviour of capsaicin is biphasic or mixed-competitive
 w x.as for several other inhibitors cf. Refs. 21,22 .
Table 1 lists other plant products that do not belong
to families of specific inhibitors of complex I such as
w xpapaverine, a compound present in opium 24 .
4.7. Ubiquinones
Short-chain quinones such as Q-2, Q-3 and octyl-Q
function both as substrates and inhibitors of NADH
w xoxidation in mammalian mitochondria 25–28,67 .
These quinone analogues accept electrons from com-
w xplex I and become inhibitory once reduced 25,27 , a
Notes to Table 2:
a I minimal in beef or rat mitochondrial preparations with the assay system indicated NADH:O represents both NADH oxidase50 2
.determined spectrophotometrically and site one respiration determined with the oxygen electrode . Due to the abundance of data, the
major reference assay is NADH–Q-1 reductase.
bRelative to the I of rotenone assayed under the same conditions.50
cDPI inhibits also the oxidation of NADH by either ferricyanide or DCIP in the absence of exogenous Q analogues, especially in purified
w xcomplex I 55 .
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suicide-like action that seems to derive from
semiquinone instability, since it increases oxygen
w xradical production in complex I 25,28 . The hydrox-
ydecyl Q analogue idebenone is more potent than
w xQ-2 and specifically inhibits membrane potential 28 ,
which raises some worries for its use as a nootropic
w xdrug 109 .
5. Synthetic and commercial inhibitors
5.1. Pesticides and agrochemicals
A new series of pesticides inhibiting complex I has
w xbeen developed in the last few years 5,6 and now
commercialized as acaricides. SAN547A and
w xSAN548A 5 are N-alkyl-4-aminoquinazolines re-
w xlated to the pesticide fenazaquin 110–112 and prob-
ably constitute the most potent synthetic inhibitors of
 . complex I Table 2 . Fenpyroximate tert-butyl
 . E -a- 1,3-dimethyl-5-phenoxypyrazol-4-ylmethyle-
. 4 w xneamino-oxy -p-toluate 113 is the only new pesti-
 .cide mentioned in the latest Merck Index 1996 and
inhibits beef complex I with a potency equivalent to
 w x.that of rotenone Table 2, cf. Refs. 7,22,113 . Al-
though fenpyroximate displaces labelled dihydro-
w xrotenone 6 , it has been suggested to act differently
from rotenone, mainly because it inhibits bacterial
w xglucose dehydrogenase like piericidin 7 . Pyridaben
  .2-tert-butyl-5- 4-tert-butylbenzylthio -4-chloro-
 . 4pyridazin-3 2h -one is a pyrazole acaricide that
seems to be superior to rotenone as inhibitor of
w x  .mammalian complex I 5,114 Table 2 . Pyridaben is
w xalso more potent than tebufenpyrad 115
  .n- 4-tert-butylbenzyl -4-chloro-3-ethyl-1-methyl-5-
4  .pyrazolecarboxamide Table 2 that is commercial-
w xized with the tradename pyranica 116,117 .
Among benzimidazole compounds with insectici-
dal properties, 1- 3,7-dimethyl-7-isobutyloxy-2-oc-
. w xtenyl -2-methylbenzimidazole 118 seems to be more
potent than rotenone in mammalian mitochondria
 w x.Table 2, cf. Refs. 7,118–120 . Related to benzimi-
dazoles are the insecticide synergistic 6-chloro-
w x1,2,3-benzothiadiazole 30 and various substituted
imidazo-thiazoles designed to mimic anthelmintic
w x  . wdrugs 31,121 . 2-methyl-6- 2-thienyl imidazo 2,1-
x  .b thiazole 2M-TIO seems to functionally compete
with myxothiazol and rotenoids, but not rolliniastatin-
w x2 31 . Recently, pyrethroid insecticides such as
cyalothrin have also been found to inhibit complex I
w x29 .
5.2. Drugs and toxins
Whereas complex I is the target for new pesticides
in agrochemistry, complex I inhibition is an increas-
ing toxicological problem, since it constitutes an
undesired side-effect of several drugs used in
medicine. Indeed, many pharmacologically important
compounds inhibit NADH–Q reductase and their po-
tency in isolated mitochondria, albeit weak when
 .compared with acaricide inhibitors Table 2 , is not
wdirectly proportional to the pathological effects 34–
x37,122 .
5.2.1. Tranquillizers
The tranquillizer barbiturate amytal 5-ethyl-5-iso-
.amylbarbituric acid is the oldest established inhibitor
w x of complex I 4,9,10,32 . Meperidine 1-methyl-4-
4phenyl-4-piperidinecarboxylic acid ethyl ester , also
called pethidine or demerol, is another analgesic drug
w xknown to inhibit complex I 33,63 . Werner and
coworkers have synthetized hydrophobic analogues
which are about 100-fold more potent than pethidine
w xin inhibiting NADH–Q reductase 33 and a radioac-
tive analogue which apparently is not displaced by
w xrotenone 123 . This agrees with enzymatic data
showing that meperidine or demerol is non-exclusive
w xwith rotenoids and other inhibitors of complex I 17 .
5.2.2. Neurotoxins
The neurotoxin 1-methyl-4-phenyl-1,2,3,4,-tetra-
 .hydropyridine MPTP induces parkinsonism in hu-
mans once transformed into the pyridinium metabo-
lite MPPq, which is responsible for the specific
w x qtoxicity in dopaminergic neurons 34,35,122 . MPP
is a rather weak inhibitor in broken mitochondria or
SMP, but in coupled mitochondria is actively accu-
mulated in the matrix due to its positive charge, with
w xa dramatic increase in potency 34–36,122 . Some
4X-alkyl analogues of MPPq are inhibitory in the
w xmicromolar range 36,37 and displace either rotenone
or piericidin A from its binding site in complex I
w x4,95,124,125 , but seem to have two distinct interac-
w xtion sites 36,37,95 . Extensive research has been
undertaken to find compounds with an action similar
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to that of MPPq and hopefully rationalize the sponta-
neous occurrence of Parkinson’s disease. Potential
candidates include indole-derived-b-carboline com-
w xpounds such as harmane 38 , the antiseptic dequalin-
w x w xium 43 , laser dyes 35 and the naturally-occurring
w xaminoethylcysteine ketimine dimer 39 and tetrahy-
 . w xdro-isoquinoline TIQ 24,126,40 . Finally, dopamine
and other catecholamine neurotransmitters have well
w xknown neurotoxic effects 127 that are possibly cor-
w xrelated to complex I inhibition 24,127,128 . This
correlation, however, is not proven yet.
5.2.3. Neuroleptic drugs
Anti-psychotic or neuroleptic drugs have long been
suspected to interfere with mitochondrial function
w x129,130 . The common side-effects of neuroleptic
w xtreatment include parkinsonism 131 , which has been
recently correlated to complex I inhibition in isolated
w xmitochondria 41 . Further correlations between the
side-effects of neuroleptic medication and parkinson-
ism derive from the discovery of pyridinium metabo-
 X lites of the drug haloperidol 4 -fluoro-4- 4-hydroxy-
. 44-p-chorophenylpiperidino butyrophenone in pa-
w x qtients 132,133 . These metabolites resemble MPP
not only in structure, but also in their mode of
w xcomplex I inhibition 42 .
5.2.4. Piperazine drugs
Recently, some commercial drugs derived from
 .piperazine diethylenediamine have been found to
inhibit complex I in the micromolar range Table 2,
w x.cf. R efs . 4 4 ,4 5 . T h ey in c lu d e th e
w xanticonvulsantrantihistaminic cinnarizine 44 and the
 w  .antianginal ranolazine 1- 3- 2-methoxyphenoxy -2-
x w  .hydroxypropyl -4- N- 2,6-dimethylphenyl carbamoyl-
x 4 w xmethyl piperazine 45 . Ranolazine has some unusual
features as complex I inhibitor, since it displays an
w xuncompetitive behaviour with respect to Q-1 45
w xsimilarly to annonaceous acetogenins 8 .
5.3. Phenolic chemicals
Besides catechol, several other phenolic com-
 .pounds inhibit complex I. 4-nonylphenol NP , a
pollutant derived from non-ionic detergents, is more
 .potent than 2,4-dinitrophenol DNP and other uncou-
plers such as carbonyl cyanide-m-chlorophenylhy-
 .  .drazone CCCP Table 2 . NP appears to compete
with quinol product inhibitors in complex I and is
mutually exclusive with stigmatellins and myxothia-
 .zol A. Ghelli, M. Degli Esposti, unpublished data .
A series of 2-alkyl-dinitrophenols has been developed
as general Q antagonist inhibitors, but their inhibition
w xof complex I is only partial 47 . Related to nitrophe-
  . n o ls is V aco r 1 - 4 -n itro p h en y l -3 - 3 -
. 4pyridylmethyl urea , a rat poison that induces an
acute condition of insulin-dependent diabetes in hu-
w xmans 134 . Complex I inhibition is responsible for
w xthe diabetogenic action of Vacor 46 .
5.4. Quinone antagonists
Oettmeier and coworkers have synthesized new
w xquinone-related inhibitors 48,49,135 . Acridones with
a 4-alkyl tail of eight carbons display maximal po-
tency for complex I, which is about one-order of
w xmagnitude lower than that of rotenone 48,135 . Bind-
ing studies have shown an apparent displacement of
w xacridones by rotenone 6,135 . The 2-n-undecyl-3-
methyl analogue is the most potent of the quinolone
series, even more than its related aurachins in both
w xcomplex I and cytochrome bc complexes 49 . The1
acridone and quinolone inhibitors presumably act as
Q antagonists in complex I, but they do not behave
w xcompetitively with Q-1 48 .
5.5. Fluorescent dyes
Acridones are closely related to acridines and fluo-
resceins, which include many fluorescent dyes used
in biological studies. The mitochondrial toxicity of
potential-sensitive dyes such as carbocyanines has
w xlong been known 136 and essentially derives from
complex I inhibition, as established in extensive stud-
w xies 50,137–139 . Erythrosine iodoacetamide, a fluo-
rescein derivative, probably is the most potent dye
 w x.inhibiting complex I Table 2, cf. Refs. 50,84 ; its
binding to isolated complex I is mutually exclusive
w xwith DB but not with rotenone 84 . It is noteworthy
w xthat among oxonol dyes, including tinopal 72 , only
oxonol-VI does not inhibit complex I.
5.6. Group reagents
The classical carboxyl reagent dicyclohexyl-carbo-
 . w xdiimide DCCD 53 and the metal chelator o-
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phenanthroline have been found to inhibit complex I,
w xas well as other membrane systems 54,140 . Con-
 .versely, the flavin reagent diphenyleneiodonium DPI
w xinhibits complex I with high potency 55 . Although
originally reported as inhibitor of the NADH–Q re-
w xductase activity 52 , DPI covalently attacks the FMN
cofactor after reduction of isolated complex I and
thus blocks electron transport to hydrophilic accep-
w xtors such as DCIP 55 .
6. Functional classification of inhibitors of
NADH–Q reductase
In examining the variety of complex I inhibitors it
emerges that several compounds seem to act differ-
ently from rotenone. Rotenone itself is likely to bind
w xto two sites 4,68,94 , as originally indicated by
w xbinding studies with piericidins 11,13,14,91 . Indeed,
concentrations of rotenone that saturate its specific
site do not significantly displace bound piericidin A
w x11,13 , which suggests that the binding of the two
inhibitors is either independent or overlapping only in
part. Moreover, some new inhibitors such as myxo-
thiazol are non exclusive with either rotenone or
w xpiericidin 17,58 . How can we distinguish function-
ally different sites for complex I inhibitors?
There is an increasing consensus of opinion that
complex I has multiple Q reaction sites, but it is
arduous to define a clearcut distinction among these
sites. Perhaps most compelling is the theoretical con-
sideration that no less than two Q action sites need to
be present in complex I to account for the generally
accepted stoichiometry of two protons per electron
w x1–4,58 . A consequence of this minimal requirement
is that some inhibitors could interfere with protonmo-
tive reactions differently from other inhibitors de-
pending on their interaction with a given Q site. In
fact, one of the two piericidin A sites affects more
potently energy-dependent RET than NADH oxida-
Table 3
Functional classification of complex I inhibitors
Inhibitor type and action Representative inhibitors Likely inhibitors
Type A—quinone antagonists Rolliniastatin-2 other annonaceous acetogenins
a .Piericidin A first site Erythrosin iodoacetamide
Idebenone Aurachin A
Phenalamid
Ranolazine
Type B—semiquinone antagonists Rotenone other rotenoids
a .Piericidin A second site Ubicidins
bPiericidin B Reduced Q-2
 .Aureothin 4-alkyl-quinazolines SAN 547A
Amytal Pyrazole acaricides
4-alkyl-acridones Squamocin
X q c4 -alkyl-MPP analogues Otivarin
Phenoxan Quinolones
X q cType C—quinol antagonists Quinol products 4 -alkyl-MPP analogues
Xbreduced Q-2 4 -alkyl-pyridines
Myxothiazol Myxalamid
Stigmatellin Vacor
TDS Carbocyanine dyes
2M-TIO Acridine dyes
 .Meperidine Demerol DNP and other uncouplers
NP
a w xPiericidin A has two sites 4,13,14,94 .
bQ-2 forms unstable semiquinones upon reduction and leads to quinol occupation of the site where normally hydrophobic Q analogues
 w x.enter complex I Fig. 1, cf. Ref. 28 . Reduced Q-2 also acts at the quinol site.
c q w x4-alkyl analogues of MPP have two sites of interaction 36,37 .
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w xtion 13,94 ; most likely, rolliniastatin-2 specifically
w xinteracts at this site 8,58 . By contrast, rotenone
inhibits more effectively NADH oxidation than en-
w xergy-dependent RET 8,68,141 and is less efficient
than rolliniastatin-2 in inhibiting the proton pumping
activity of complex I under limited turnover condi-
w xtions 58 . Rotenone and piericidin A also differ in
their kinetic behaviour towards Q analogue sub-
wstrates. Rotenone is consistently non-competitive 6–
x8,31,33,22,48,45 , whereas piericidin A is competi-
w xtive with endogenous Q 91,14,94 and partially com-
w xpetitive with some exogenous Q analogues 7 . Note
Fig. 1. A diagram for the action of the three fundamental types of inhibitors of NADH–Q reductase. The diagram represents the minimal
w xsteps of Q reduction by complex I and derives from the dual Q-gated pump model 58 modified to account for the likely protonmotive
w xrole of cluster N2 3 . The first electron from NADH, through oxidoreduction of cluster N2, reduces a firmly bound Q molecule at site B,
w xforming a stabilized ubisemiquinone that corresponds to the rotenone-sensitive radical 142–144 , and produces some charge separation
w x51 . The second electron from NADH is transferred by the low-potential cofactors to another molecule of ubiquinone which enters the
w xcomplex at the hydrophobic site A and activates proton pumping 58 . Rolliniastatin-2 and other type A inhibitors antagonize Q at this
site. The second semiquinone formed at site A then dismute with the more stable semiquinone at site B, producing the ubiquinol product
that leaves the complex. Oxidized Q remains at site B after dismutation to re-initiate the catalytic cycle. The dismutation of the two
w xsemiquinones is a critical step in the proper function of complex I 143 . With exogenous analogues such as Q-2 that have a pronounced
semiquinone instability, the dismutation step can diverge from the normal route, producing quinol at the ‘wrong’ site, as illustrated by the
white arrow and the rightmost enzyme form in the diagram. I hypothesize that type C inhibitors act by effectively enhancing this
unproductive form of the enzyme at steady-state. To do so, they could either interact directly with the quinol-releasing site, or interfere
with the dismutation reaction of the semiquinones in sites A and B. Presumably, the dismutation reaction of the two semiquinones is also
associated with charge separation across the membrane, and its destabilization may enhance the production of oxygen radical species by
complex I.
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that rolliniastatin-2 shows competitive behaviour with
idebenone and decyl-plastoquinone M. Degli Es-
.posti, A. Ghelli, unpublished data but uncompetitive
w xbehaviour with other Q analogues 8 .
By combining these different properties, complex I
inhibitors can be broadly classified into inhibitors
acting like rolliniastatin-2 or piericidin A at one of
. its two sites and inhibitors acting like rotenone at its
.most specific site . These two types of inhibitors
would partially correspond to class I and II, respec-
w xtively, that were proposed previously 7 and include
several other compounds chemically unrelated to
rotenoids or piericidins. However, there are some
inhibitors that fit neither the rotenone nor the rollini-
astatin-2rpiericidin A type. For instance quinol ana-
logues, especially Q2H , are particularly potent for2
the membrane potential generation of complex I and
the redox activity with hydrophilic substrates such as
w xQ-1, that promote inefficient proton pumping 25,67
—presumably because these quinones are protonated
in the aqueous phase and not within the membrane
like natural ubiquinone. Myxothiazol, stigmatellin,
NP, capsaicin, demerol and some cationic MPPq
analogues also appear to interact with a hydrophilic
w xsite in complex I 17,37 and share the inhibitory
properties of quinols. Hence, these compounds could
form a third type of complex I inhibitors which
w xessentially act as the quinol product 58 .
Given the above, I propose a functional classifica-
tion of various complex I inhibitors into three funda-
 .mental types Table 3 that interfere with basic steps
in Q reduction as schematically illustrated in Fig. 1.
In brief, they act as: A, direct antagonists of Q
substrate at the entry of the hydrophobic site in the
complex; B, antagonists of the semiquinone interme-
diate stabilized within the complex; and C, antago-
nists of either the formation or release of the quinol
product. Different chemical determinants are associ-
ated with these three types of inhibitors. Type A
inhibitors possess a hydroxyl group both in the cyclic
head and the hydrophobic tail, optimally spaced by
10–12 carbons as in piericidin A, rolliniastatin-2 and
idebenone. Conversely, type B inhibitors have only
H-bonding acceptors in the head and no hydroxy
groups in the tail. In fact, even piericidins without the
hydroxyl group in the tail displace bound rotenone
w xbut not bound piericidin A 11,14 . By using these
w xinferences and earlier data 7 , phenalamid, aurachins
and also erythrosin could be classified as type A
inhibitors. Type C inhibitors, instead, generally pos-
sess a hydroxy or amino group in the head. However,
the hydrophilic site at which they are supposed to
interact is likely to have a rather weak specificity for
recognizing chemically different compounds, and may
as well accept substances that bind with more affinity
to other sites in complex I, e.g. rotenone.
Two qualifications are required with regard to the
 .new classification proposed here Table 3 . First, for
some inhibitors the classification is essentially based
upon inferences that need to be experimentally tested.
Secondly, several inhibitors besides rotenone and pie-
ricidin A could interact at multiple sites depending on
their concentration. Consequently, binding displace-
ment results could over-estimate the extent of mutual
overlapping in the specific interaction of certain in-
hibitors. However, by combining the results of com-
plementary approaches it should be possible to define
the most specific action of any inhibitor of complex I
according to the three fundamental types outlined in
Table 3.
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